PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors
Benedetta Pellegrino(University of Parma), V. Serra Elizalde, Miguel Ángel Pujana(Bellvitge University Hospital), M. Castroviejo, Flaminia Pedretti, Roberta Fasani(Vall d'Hebron Institute of Oncology), Mark J. O’Connor, Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Alba Llop‐Guevara(Vall d'Hebron Institut de Recerca), Francesca Mateo(Institut d'Investigació Biomédica de Bellvitge), Alberto Cedro‐Tanda(Centro Universitario Anglo Mexicano), Paolo Nucíforo(Vall d'Hebron Institute of Oncology), Alena Gros(Unknown), Judith Balmañà(Vall d'Hebron Hospital Universitari), Cristina Cruz(Vall d'Hebron Institut de Recerca)
Cited by 3
Related Papers
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
|Journal of Clinical Investigation|2014|1.1k
Network modeling links breast cancer susceptibility and centrosome dysfunction
|Nature Genetics|2007|634